Atomwise’s Post

View organization page for Atomwise, graphic

20,370 followers

We're excited to announce the nomination of our very first AI-driven development candidate, focused on TYK2 inhibition. This marks a significant milestone in our journey to revolutionize drug discovery and development through artificial intelligence. Joining us on this incredible venture is Dr. Neely Mozaffarian, MD, PhD, who has been appointed as our new Chief Medical Officer. With her expertise and leadership, we're poised to advance groundbreaking solutions that could transform the lives of millions. At Atomwise, we're committed to using AI to accelerate drug discovery and improve patient outcomes. This appointment and our strategy are a testament to our dedication to creating #FirstInClass and #BestInClass medicines for patients. Stay tuned for more updates as we continue to push the boundaries of what's possible in medicine and science! #AI #DrugDiscovery #HealthcareInnovation #TYK2Inhibition #Atomwise https://lnkd.in/ecSizR_6

Atomwise Announces Nomination of its First AI-Driven Development Candidate Focused on TYK2 Inhibition and Appoints Neely Mozaffarian, MD, PhD as Chief Medical Officer

Atomwise Announces Nomination of its First AI-Driven Development Candidate Focused on TYK2 Inhibition and Appoints Neely Mozaffarian, MD, PhD as Chief Medical Officer

businesswire.com

Megan Conlon, PhD

Sr Territory Sales Manager at BPS Bioscience Inc.

9mo

This is super exciting, huge congratulations to the Atomwise team! 🎉

Like
Reply
Ho Leung Ng

AI/computational drug discovery leader. Seeking new opportunities.

9mo

Best wishes to the Atomwise team!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics